TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05836259: First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-201, a Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Myosin Binding Protein C

Sponsor: Tenaya Therapeutics · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 30 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,495,660

Rescue Site Savings

+$987,700

Unlock Full NCT05836259 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05836259 Rescue Dossier →